Scarica l'app Stockscreener
42.17
0.64%
0.27
Dopo l'orario di chiusura:
42.17
Precedente Chiudi:
$41.90
Aprire:
$42
Volume 24 ore:
805.26K
Relative Volume:
0.98
Capitalizzazione di mercato:
$3.25B
Reddito:
$13.17M
Utile/perdita netta:
$-199.06M
Rapporto P/E:
-15.39
EPS:
-2.74
Flusso di cassa netto:
$-156.53M
1 W Prestazione:
+2.16%
1M Prestazione:
+18.26%
6M Prestazione:
+24.84%
1 anno Prestazione:
-1.06%
Intervallo 1D:
$41.68
$42.71
Intervallo di 1 settimana:
$39.34
$42.71
Portata 52W:
$26.74
$46.00
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Nome
Xenon Pharmaceuticals Inc
Settore
Industria
Telefono
(604) 484-3300
Indirizzo
200 - 3650 GILMORE WAY, BURNABY
Confronta XENE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
42.17 | 3.13B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-03 | Ripresa | Wells Fargo | Overweight |
| 2025-05-07 | Iniziato | Chardan Capital Markets | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-01 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-04 | Iniziato | Citigroup | Buy |
| 2023-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Iniziato | Goldman | Buy |
| 2022-12-12 | Iniziato | Cowen | Outperform |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-10-19 | Iniziato | Raymond James | Outperform |
| 2022-08-29 | Iniziato | BofA Securities | Buy |
| 2022-07-21 | Iniziato | JP Morgan | Overweight |
| 2021-10-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-10-02 | Iniziato | SVB Leerink | Outperform |
| 2020-07-21 | Iniziato | Needham | Buy |
| 2020-06-01 | Ripresa | Jefferies | Buy |
| 2020-03-25 | Iniziato | Wedbush | Outperform |
| 2020-01-08 | Iniziato | William Blair | Outperform |
| 2019-09-20 | Iniziato | Guggenheim | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2017-03-13 | Iniziato | Jefferies | Buy |
| 2016-10-21 | Iniziato | Stifel | Buy |
| 2016-09-26 | Iniziato | Guggenheim | Buy |
| 2016-04-14 | Reiterato | Jefferies | Buy |
| 2015-10-30 | Ripresa | Jefferies | Buy |
| 2014-12-02 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Xenon Pharmaceuticals Inc Borsa (XENE) Ultime notizie
Will Xenon Pharmaceuticals Inc. price bounce be sustainableJuly 2025 Pullbacks & Weekly Market Pulse Updates - newser.com
Can a trend reversal in Xenon Pharmaceuticals Inc. lead to recoveryPortfolio Update Report & Stepwise Entry/Exit Trade Alerts - newser.com
Xenon Pharmaceuticals Inc. Announces Appointment of Tucker Kelly as Member of Its Senior Executive Team - MarketScreener
Xenon Pharmaceuticals Appoints Tucker Kelly as CFO to Drive Commercialization Efforts - TipRanks
Xenon Pharmaceuticals Inc. Appoints Tucker Kelly as Chief Financial Officer to Advance Commercialization of Azetukalner - Quiver Quantitative
225,000-Share Option: Xenon Appoints Tucker Kelly as CFO with 30,000 RSUs preparing for topline data - Stock Titan
Xenon Pharmaceuticals’ (XENE) Sell (D-) Rating Reaffirmed at Weiss Ratings - Defense World
Investors Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Visualizing Xenon Pharmaceuticals Inc. stock with heatmapsJuly 2025 Catalysts & Capital Efficiency Focused Strategies - newser.com
Why Xenon Pharmaceuticals Inc. stock is trending among retail tradersWeekly Trade Report & Low Risk Investment Opportunities - newser.com
Is Xenon Pharmaceuticals Inc a good long term investmentTechnology Stock Trends & Minimal Capital Trading Tips - earlytimes.in
Xenon Pharmaceuticals Inc.’s volatility index tracking explained2025 AllTime Highs & Low Drawdown Investment Ideas - newser.com
Will Xenon Pharmaceuticals Inc. stock maintain growth storyPortfolio Return Report & Technical Confirmation Trade Alerts - newser.com
Published on: 2025-10-13 08:53:34 - newser.com
Mirae Asset Global Investments Co. Ltd. Purchases 403 Shares of Xenon Pharmaceuticals Inc. $XENE - Defense World
Will Xenon Pharmaceuticals Inc. stock attract more institutional investorsWeekly Trade Recap & Entry Point Confirmation Alerts - newser.com
Xenon Pharmaceuticals (XENE): Exploring Valuation After Recent Share Price Momentum - Yahoo Finance
Leerink Partners Remains a Buy on Xenon (XENE) - The Globe and Mail
Evaluating Xenon Pharmaceuticals (XENE): Is the Current Valuation Justified After Recent Share Price Momentum? - Sahm
Research Analysts Issue Forecasts for XENE FY2025 Earnings - MarketBeat
What is Bloom Burton’s Estimate for XENE FY2025 Earnings? - Defense World
Xenon Pharmaceuticals Issues Equity Inducement Grants to New Employees - MSN
Will Xenon Pharmaceuticals Inc. stock attract ESG investorsDay Trade & Free Weekly Watchlist of Top Performers - newser.com
Is Xenon Pharmaceuticals Inc. stock attractive for income investors2025 Trading Recap & Capital Efficiency Focused Ideas - newser.com
Is Xenon Pharmaceuticals a Smart Investment After Its New Clinical Trial Partnership? - Sahm
What analysts say about Xenon Pharmaceuticals Inc stockInsider Selling Patterns & Budget Friendly Trading Strategies - earlytimes.in
Brokers Offer Predictions for XENE FY2026 Earnings - MarketBeat
Bloom Burton Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to "Strong-Buy" - MarketBeat
Xenon Pharmaceuticals’ (XENE) Outperform Rating Reaffirmed at William Blair - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Given “Buy” Rating at Chardan Capital - Defense World
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
77,750 Options: Xenon Pharmaceuticals Grants Equity to Seven New Hires at $39.20, Oct 2, 2025 - Stock Titan
Xenon Pharmaceuticals' (XENE) Outperform Rating Reiterated at William Blair - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Receives "Buy" Rating from Chardan Capital - MarketBeat
XENE: Chardan Capital Maintains Buy Rating with $55 Price Target - GuruFocus
Chardan Capital Maintains Xenon Pharmaceuticals (XENE) Buy Recommendation - Nasdaq
Xenon Pharmaceuticals Inc. (XENE) Stock Analysis: Biotechnology Innovator with a 38.93% Upside Potential - DirectorsTalk Interviews
Transcript : Xenon Pharmaceuticals Inc.Special Call - MarketScreener
Will Xenon Pharmaceuticals Inc. stock recover after recent dropJobs Report & Verified Swing Trading Watchlist - newser.com
Is it time to cut losses on Xenon Pharmaceuticals Inc.Market Growth Summary & Safe Capital Investment Plans - newser.com
Xenon Pharmaceuticals Inc. $XENE Shares Purchased by J. Safra Sarasin Holding AG - MarketBeat
Xenon Pharmaceuticals announces executive changes - MSN
HighMark Wealth Management LLC Has $817,000 Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Inc. stock chart pattern explainedWeekly Volume Report & Low Risk Entry Point Tips - newser.com
Xenon Pharmaceuticals Inc Azioni (XENE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Xenon Pharmaceuticals Inc Azioni (XENE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MORTIMER IAN | PRESIDENT, CEO & INTERIM CFO |
Oct 01 '25 |
Sale |
40.16 |
25,000 |
1,004,000 |
31,302 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):